Compare Air Products & Chemicals, Inc. (APD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Summit Therapeutics Inc — how do they compare? Air Products & Chemicals, Inc. trades at $296.7 (market cap $66.70B), while Summit Therapeutics Inc trades at $15.03 (market cap $11.84B). The key difference: Air Products & Chemicals, Inc. is far larger — about 5.6× Summit Therapeutics Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.42% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| APD | SMMT | |
|---|---|---|
Market Cap | $66.70B | $11.84B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $29.32 |
52-Week Low | $230.42 | $13.05 |
Enterprise Value | $84.11B | $11.26B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.
The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.
Summit Therapeutics (SMMT) trades at $15.25, down 1.49% today, with technical indicators showing bearish momentum despite recent positive clinical trial results for its lead oncology drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while cash flow trends show increasing operational cash burn. Analyst consensus remains bullish with 14 buy ratings and a $15.57 price target, reflecting optimism around the drug's potential despite financial challenges.
SMMT presents a high-risk, high-reward opportunity centered on binary clinical outcomes. Near-term catalysts include FDA review of ivonescimab, but substantial financial losses and dependence on a single asset create significant volatility. The stock's outlook hinges entirely on successful drug commercialization, with current valuations disconnected from fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
